(Q36414523)

14 August 2017

1 reference

title

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma (English)

1 reference

14 August 2017

1 reference

Ribatti D

1

1 reference

14 August 2017

Nico B

series ordinal

2

1 reference

14 August 2017

Vacca A

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

6 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

25

1 reference

14 August 2017

31

1 reference

14 August 2017

4257-4266

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1209456

14 August 2017

0 references

cites work

Molecular characterization of the tumor microenvironment in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Analysis of the role of chemokines in angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Interleukin 6 induces the expression of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Matrix metalloproteinases and the development of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Mast cell heterogeneity in B-cell non-Hodgkin's lymphomas: an ultrastructural study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Ultrastructural analysis of mast cell recovery after secretion by piecemeal degranulation in B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical–biological features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Cytokines and signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Downstream effectors of oncogenic ras in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Roles of nitric oxide in tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Multiple myeloma: evolving genetic events and host interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Interleukin-6 inhibits apoptosis of malignant plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Identification of genes modulated in multiple myeloma using genetically identical twin samples

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Vascular endothelial growth factor (VEGF) and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

The distribution of secondary growths in cancer of the breast. 1889

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

CXCR3-binding chemokines in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Vascular endothelial growth factor and its receptors in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Angiogenesis and anti-angiogenesis in hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

The involvement of endothelial progenitor cells in tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Mast cell contribution to angiogenesis related to tumour progression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Therapeutic renaissance of thalidomide in the treatment of haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Endothelial cells in the bone marrow of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Bone marrow angiogenesis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Cellular response to hypoxia involves signaling via Smad proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Circulating endothelial progenitor cells in multiple myeloma: implications and significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1209456

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1209456

1 reference

14 August 2017

1 reference